Are YOU at risk of liver disease? Take this test to find out
The 11-step calculator, created by the British Liver Trust, asks users questions about several known risk factors of the 'silent killer'. The tool takes just minutes to answer. (Source: the Mail online | Health)
Source: the Mail online | Health - June 21, 2018 Category: Consumer Health News Source Type: news

Liver disease symptoms: Seven signs your organ has been severely damaged by alcohol
LIVER disease symptoms, caused by excessive alcohol intake, usually only show when the organ has been severely damaged. It ’s important to recognise these signs as repeated damage can lead to alcoholic liver cirrhosis. There are seven symptoms to look out for. (Source: Daily Express - Health)
Source: Daily Express - Health - June 19, 2018 Category: Consumer Health News Source Type: news

Albireo Appoints Jason G. Duncan as General Counsel and Secretary
BOSTON, June 18, 2018 -- (Healthcare Sales & Marketing Network) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Jason G. Duncan as Gene... Biopharmaceuticals, Personnel Albireo Pharma, bile acid modulator, liver disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 18, 2018 Category: Pharmaceuticals Source Type: news

Liver Cancer Doubled in High-Income Countries Liver Cancer Doubled in High-Income Countries
Rates of liver cancer have doubled since the 1990s in high-income countries and are largely due to infection with hepatitis B and C, as well as nonalcoholic fatty liver disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Israeli Company Galmed Gets Positive Trial Results for Liver Drug Israeli Company Galmed Gets Positive Trial Results for Liver Drug
Galmed Pharmaceuticals said on Tuesday patients in a mid-stage trial for its treatment for non-alcoholic steatohepatitis (NASH), a fatty liver disease linked to obesity, showed a statistically significant reduction in liver fat.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 13, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Remember Last Year's Hepatitis A Outbreak? This Year It's So Much Worse.
Cases of the potentially deadly liver disease have nearly doubled as outbreaks spread nationwide. (Source: Science - The Huffington Post)
Source: Science - The Huffington Post - June 13, 2018 Category: Science Source Type: news

Study: VA-sponsored telementoring improved survival rates for liver disease by 54 percent
Patients of doctors who participated in a Veteran Affairs-run telemedicine consultation program were 54 percent more likely to survive chronic liver disease than a matched cohort of patients of non-participating doctors, according to a new retrospective study from the University of Michigan. (Source: mobihealthnews)
Source: mobihealthnews - June 13, 2018 Category: Information Technology Source Type: news

Smoking With Liver Disease - A No-No
Title: Smoking With Liver Disease - A No-NoCategory: Doctor's& Expert's views on SymptomsCreated: 8/6/2001 12:00:00 AMLast Editorial Review: 6/13/2018 2:55:09 PM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - June 13, 2018 Category: Nutrition Source Type: news

Israeli company Galmed gets positive trial results for liver drug
TEL AVIV (Reuters) - Galmed Pharmaceuticals said on Tuesday patients in a mid-stage trial for its treatment for NASH, a fatty liver disease linked to obesity, showed a statistically significant reduction in liver fat. (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Medical News Today: What causes coffee ground vomitus?
Coffee ground vomitus is dark-colored vomit that has blood in it. Possible causes include gastric ulcers, gastritis, liver disease, and cancer. Anyone who vomits blood should seek immediate medical attention. In this article, we look at the causes, symptoms, diagnosis, and treatment of coffee ground vomitus. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 12, 2018 Category: Consumer Health News Tags: GastroIntestinal / Gastroenterology Source Type: news

Video conferencing helps PCPs improve liver disease care, survival rates
(Michigan Medicine - University of Michigan) Providing physicians with virtual access to specialists can be lifesaving to liver disease patients. A new study by University of Michigan gastroenterologists finds that it boosts survival rates by 54 percent. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2018 Category: International Medicine & Public Health Source Type: news

High Costs for Diagnosis, Care of Nonalcoholic Fatty Liver Disease
MONDAY, June 11, 2018 -- The health care costs associated with nonalcoholic fatty liver disease (NAFLD) are considerable, especially at first diagnosis, according to a study published online May 18 in Hepatology. Alina M. Allen, M.D., from the Mayo... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 11, 2018 Category: Pharmaceuticals Source Type: news

Albireo Elects Anne Klibanski and Stephanie Okey to Board of Directors
BOSTON, June 08, 2018 -- (Healthcare Sales & Marketing Network) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the election of Anne Klibanski, M.D., and ... Biopharmaceuticals, Gastroenterology, Personnel Albireo Pharma, bile acid modulator, liver disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 8, 2018 Category: Pharmaceuticals Source Type: news

Digestive Disease Week, June 2-5
Digestive Disease Week 2018 The Digestive Disease Week annual meeting sponsored by the American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, and Society for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 7, 2018 Category: Pharmaceuticals Source Type: news

Bezafibrate Normalizes Liver Enzymes in PBC
(MedPage Today) -- Fibrate shows promise for rare autoimmune liver disease (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 7, 2018 Category: Gastroenterology Source Type: news

Too young for such an "old" condition: 8-year-olds now being diagnosed with nonalcoholic fatty liver disease
(Natural News) Adults who have an unhealthy lifestyle are often diagnosed with nonalcoholic fatty liver disease (NAFLD). But according to a study, there is an alarming link “between childhood obesity and juvenile liver health problems.” The study on children involved researchers from Harvard Medical School based on Project Viva of Massachusetts. It confirmed a connection between childhood obesity and... (Source: NaturalNews.com)
Source: NaturalNews.com - June 6, 2018 Category: Consumer Health News Source Type: news

Antibody blocks inflammation, protects mice from hardened arteries and liver disease
(University of California - San Diego) Researchers at University of California San Diego School of Medicine discovered that they can block inflammation in mice with a naturally occurring antibody that binds oxidized phospholipids (OxPL), molecules on cell surfaces that get modified by inflammation. Even while on a high-fat diet, the antibody protected the mice from arterial plaque formation, hardening of the arteries and liver disease, and prolonged their lives. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 6, 2018 Category: International Medicine & Public Health Source Type: news

Pre-op Avatrombopag Curbs Platelet Need in Patients With Liver Disease Pre-op Avatrombopag Curbs Platelet Need in Patients With Liver Disease
Pre-procedural avatrombopag (Doptelet, Dova) may reduce the need for platelet transfusions or rescue procedures for bleeding in patients with chronic liver disease (CLD) and thrombocytopenia, according to findings from two phase 3 trials.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

145% climb: Madrigal Pharmaceuticals' stock soars on positive study results
Madrigal Pharmaceuticals Inc.'s stock price more than doubled Thursday, closing up 145 percent at $265.61 per share, after the company announced results from mid-stage testing of its lead new drug candidate. The experimental therapy, MGL-3196, is a once-daily oral therapy being developed as a treatment for a severe form of a liver disease known as non-alcoholic steatohepatitis or NASH. NASH is considered a silent disease that has few or no symptoms. Its is characterized by the accumulation of… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 31, 2018 Category: Biotechnology Authors: John George Source Type: news

Madrigal Pharma Shares Double After Successful Phase II Results For Fatty Liver Drug
Competition is tough for a drug to cure fatty liver disease. After today's 150% jump, is Madrigal Pharmaceuticals the next darling of the biotech sector? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 31, 2018 Category: Pharmaceuticals Authors: Karl Kaufman, Contributor Tags: NASDAQ:MDGL NASDAQ:GILD NYSE:AGN NASDAQ:VKTX NASDAQ:ICPT Source Type: news

Madrigal Pharma more than doubles after liver drug study success
(Reuters) - Madrigal Pharmaceuticals Inc's shares more than doubled after mid-stage trial data showed its lead drug reduced liver fat in patients with fatty liver disease, placing it ahead of larger rivals to tap into a potential market worth $30 billion. (Source: Reuters: Health)
Source: Reuters: Health - May 31, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Madrigal Pharma's liver drug succeeds in study, shares soar
(Reuters) - Madrigal Pharmaceuticals Inc's lead experimental drug achieved the main goal of reducing liver fat in patients with fatty liver disease in a mid-stage study, sending its shares surging 66 percent in premarket trading on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - May 31, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Madrigal Pharma's liver disease drug succeeds in study, shares soar
(Reuters) - Madrigal Pharmaceuticals Inc said on Thursday its lead experimental drug achieved the main goal of reducing liver fat in patients with a type of liver disease in a mid-stage study, sending its shares surging 40 percent in premarket trading. (Source: Reuters: Health)
Source: Reuters: Health - May 31, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

We could reverse aging by removing wrinkles inside our cells, study suggests
(University of Virginia Health System) A new discovery about the effects of aging in our cells could allow doctors to cure or prevent diabetes, fatty liver disease and other metabolic diseases -- and possibly even turn back the clock on aging itself. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 29, 2018 Category: Biology Source Type: news

California children are drinking less soda but are getting more calories from sugary sports and energy products
Children and teenagers in California are filling up on sports and energy drinks that contain similar amounts of sweeteners and pose the same health risks as soda, according to a new  study by the UCLA Center for Health Policy Research.“There should be a warning label on flavored water, sports and energy drinks that says, ‘We may seem like a healthy choice, but we’re loaded with sugar, too,’” said Joelle Wolstein, research scientist at the center and lead author of the study. “People seem unaware that these drinks have the same or even higher amounts of added sweetener...
Source: UCLA Newsroom: Health Sciences - May 24, 2018 Category: Universities & Medical Training Source Type: news

UMass Amherst chemists, team develop new blood test to quickly detect liver damage
(University of Massachusetts at Amherst) Chemist Vincent Rotello at UMass Amherst, with others at University College London, have developed a 'quick and robust' blood test that can detect liver damage before symptoms appear, offering what they hope is a significant advance in early detection of liver disease. Details appear in Advanced Materials. Their new method can detect liver fibrosis, the first stage of liver scarring that can lead to fatal disease if left unchecked, from a blood sample in 30-45 minutes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 24, 2018 Category: International Medicine & Public Health Source Type: news

CU researchers offer insights into liver disease caused by intravenous nutrition
(University of Colorado Anschutz Medical Campus) University of Colorado School of Medicine's Karim C. El Kasmi, MD, PhD, assistant professor of pediatrics, and Ronald Sokol, MD, professor of pediatrics, are authors of an article in the April 2018 Nature Communications that sheds light on the underlying cause of intestinal failure-associated liver disease and suggests new therapeutic approaches. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 23, 2018 Category: International Medicine & Public Health Source Type: news

Doptelet Approved for Liver Disease Patients Slated for a Medical Procedure
Title: Doptelet Approved for Liver Disease Patients Slated for a Medical ProcedureCategory: Health NewsCreated: 5/21/2018 12:00:00 AMLast Editorial Review: 5/22/2018 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - May 22, 2018 Category: Nutrition Source Type: news

FDA Approves Doptelet (avatrombopag) for Thrombocytopenia Patients with Chronic Liver Disease who are Undergoing a Medical Procedure
May 21, 2018 -- The U.S. Food and Drug Administration today approved Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 21, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves Doptelet (avatrombopag) for Chronic Liver Disease Patients with Thrombocytopenia who are Undergoing a Medical Procedure
May 21, 2018 -- The U.S. Food and Drug Administration today approved Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 21, 2018 Category: Drugs & Pharmacology Source Type: news

FDA OKs Platelet Booster for Liver Disease Patients FDA OKs Platelet Booster for Liver Disease Patients
Avatrombopag increases platelet counts and may decrease or eliminate the need for transfusions in patients with liver disease and thrombocytopenia who are to undergo a planned medical or dental procedure.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 21, 2018 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news

FDA OKs Doptelet for Liver Disease Patients Undergoing Procedures
MONDAY, May 21, 2018 -- Doptelet (avatrombopag) has been approved by the U.S. Food and Drug Administration to treat adults with chronic liver disease who are slated to have a medical or dental procedure. Doptelet was evaluated in a pair of clinical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 21, 2018 Category: Pharmaceuticals Source Type: news

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures
MONDAY, May 21, 2018 -- Doptelet (avatrombopag) has been approved by the U.S. Food and Drug Administration to treat adults with chronic liver disease who are slated to have a medical or dental procedure. Doptelet was evaluated in a pair of clinical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 21, 2018 Category: Pharmaceuticals Source Type: news

Platelet Stimulator OK'd for Liver Disease Patients with Scheduled Procedures
(MedPage Today) -- Avatrombopag (Doptelet) is first drug approved for this indication (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 21, 2018 Category: American Health Source Type: news

FDA approves Dova's drug
The U.S. Food and Drug Administration has approved Durham-based Dova Pharmaceuticals' first drug. The approval is for avatrombopag, which treats low platelet count in patients with chronic liver disease. According to Dova, with about 70,000 patients with CLD suffering from severe low platelet count in the U.S., the company’s lead drug is slated to be an alternative to more invasive platelet transfusions that present the possibility of infection, among other risks. Platelet count needs to be increased… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 21, 2018 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

Dova Pharma's blood disorder drug gets FDA approval
(Reuters) - The U.S Food and Drug Administration said on Monday it had approved Dova Pharmaceuticals Inc's drug to treat low blood platelet count in chronic liver disease (CLD) patients, who are scheduled to undergo a medical procedure. (Source: Reuters: Health)
Source: Reuters: Health - May 21, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure
FDA approves Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical procedure. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 21, 2018 Category: American Health Source Type: news

Doptelet Approved for Liver Disease Patients Slated for a Medical Procedure
MONDAY, May 21, 2018 -- Doptelet (avatrombopag) has been approved by the U.S. Food and Drug Administration to treat adults with chronic liver disease who are slated to have a medical or dental procedure. People with ongoing liver disease often have... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 21, 2018 Category: General Medicine Source Type: news

Medical News Today: Hepatosplenomegaly: Everything you need to know
Hepatosplenomegaly refers to an enlargement of the liver and spleen. Its causes include a variety of conditions that affect these two organs, including liver disease, HIV, anemia, infections, and cancer. In this article, we look at the causes, symptoms, how doctors diagnose hepatosplenomegaly, and treatment options. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 19, 2018 Category: Consumer Health News Tags: Liver Disease / Hepatitis Source Type: news

NAFLD Is a Growing Problem NAFLD Is a Growing Problem
Recent guidance from the American Association for the Study of Liver Diseases for the evaluation and management of patients with nonalcoholic fatty liver disease is profiled.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 18, 2018 Category: Consumer Health News Tags: Gastroenterology Expert Column Source Type: news

Fat, microRNAs, and liver disease
(Source: ScienceNOW)
Source: ScienceNOW - May 17, 2018 Category: Science Authors: Ferrarelli, L. K. Tags: twis Source Type: news

Understanding vitamin D trends in children with non-alcoholic fatty liver disease
(University of Leeds) New research charts vitamin D levels and variations in genes that determine vitamin D status in UK children diagnosed with non-alcoholic fatty liver disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 15, 2018 Category: International Medicine & Public Health Source Type: news

IRE1{alpha} prevents hepatic steatosis by processing and promoting the degradation of select microRNAs
Obesity or a high-fat diet represses the endoribonuclease activity of inositol-requiring enzyme 1α (IRE1α), a transducer of the unfolded protein response (UPR) in cells under endoplasmic reticulum (ER) stress. An impaired UPR is associated with hepatic steatosis and nonalcoholic fatty liver disease (NAFLD), which is caused by lipid accumulation in the liver. We found that IRE1α was critical to maintaining lipid homeostasis in the liver by repressing the biogenesis of microRNAs (miRNAs) that regulate lipid mobilization. In mice fed normal chow, the endoribonuclease function of IRE1α processed a subse...
Source: Signal Transduction Knowledge Environment - May 15, 2018 Category: Science Authors: Wang, J.-M., Qiu, Y., Yang, Z., Kim, H., Qian, Q., Sun, Q., Zhang, C., Yin, L., Fang, D., Back, S. H., Kaufman, R. J., Yang, L., Zhang, K. Tags: STKE Research Articles Source Type: news

UCLA faculty voice: A hangover pill? Tests on drunk mice show promise
UCLAYunfeng LuYunfeng Lu is a professor of chemical and biomolecular engineering in the UCLA Samueli School of Engineerg.  Thiscolumn appeared in the Conversation.“Civilization begins with distillation,” said William Faulkner, a writer and drinker. Although ourthirst for alcohol dates back to the Stone Age, nobody has figured out a good way to deal with the ensuing hangover after getting drunk.As a chemical engineering professor and wine enthusiast, I felt I needed to find a solution. As frivolous as this project may sound, it has serious implications. Between 8 and10 percent of emergency room visits in Am...
Source: UCLA Newsroom: Health Sciences - May 11, 2018 Category: Universities & Medical Training Source Type: news

Medical News Today: How long will I survive after a liver transplant?
Liver transplant surgery is the second most common transplant surgery in the U.S. Livers typically come from deceased donors, but transplants using parts of livers from live donors are becoming more frequent. Figures show that more than 50 percent of people who have a liver transplant survive for at least 20 years. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 10, 2018 Category: Consumer Health News Tags: Liver Disease / Hepatitis Source Type: news

How to detox yourself from sugar: A day-by-day guide
(Natural News) Did you know that quitting sugar can help lower your risk of developing diabetes, heart disease and liver disease? These health conditions have two things in common: Sugar as a culprit, and they all have a place in the list of top 15 causes of death. If your diet consists of sugar-rich foods, your blood pressure... (Source: NaturalNews.com)
Source: NaturalNews.com - May 9, 2018 Category: Consumer Health News Source Type: news

Medical News Today: What are the treatments for plantar fibroma?
A plantar fibroma is a non-cancerous growth in the foot. It grows in the plantar fascia, in the arch of the foot. It has a range of potential causes including genetics and chronic liver disease. Diagnosis is often achieved through X-ray. Treatment depends on the underlying cause. Learn more about plantar fibroma here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 8, 2018 Category: Consumer Health News Tags: Bones / Orthopedics Source Type: news

Gut check: Metabolites shed by intestinal microbiota keep inflammation at bay
(Tufts University) Researchers have elucidated a mechanism by which 'good' bacteria that reside in our gastrointestinal tract can help protect us from inflammation, and how their disruption (dysbiosis) can increase the susceptibility of the liver to more harmful forms of disease. Their study, now available in the journal Cell Reports, identified two key metabolites produced by the bacteria in mice that modulate inflammation in the host and could ultimately reduce the severity of non-alcoholic fatty liver disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 4, 2018 Category: International Medicine & Public Health Source Type: news

New research: Alcohol treatment services in England at crisis point, putting hundreds of thousands of people at risk
This report shows very clearly what action is needed and we urge policy-makers, practitioners and service providers to join together to implement these recommendations to help the hundreds of thousands of people who are in desperate need of support.” ENDS Notes to editors The report: Read the full report here. The report’s 154 respondents were drawn from a wide range of fields related to alcohol services, including nurses, GPs, those working in community safety and service providers. A full breakdown can be found in the report. Alcohol treatment: What is alcohol treatment and why is it important? Read the blog...
Source: Alcohol Research UK - May 1, 2018 Category: Addiction Authors: Julie Symes Tags: News treatment treatment services Source Type: news

Alcohol Use and Outcomes in Patients Transplanted for Non-ALD Alcohol Use and Outcomes in Patients Transplanted for Non-ALD
What are the potential consequences of alcohol use after liver transplantation in patients who received transplants for non-alcoholic liver disease?Alcohol and Alcoholism (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 1, 2018 Category: Surgery Tags: Transplantation Journal Article Source Type: news